-
1 Comment
Ion Beam Applications SA is currently in a long term uptrend where the price is trading 13.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Ion Beam Applications SA's total revenue sank by 38.9% to $110M since the same quarter in the previous year.
Its net income has dropped by 193.2% to $-12M since the same quarter in the previous year.
Finally, its free cash flow grew by 103.5% to $36M since the same quarter in the previous year.
Based on the above factors, Ion Beam Applications SA gets an overall score of 3/5.
| Exchange | BR |
|---|---|
| CurrencyCode | EUR |
| ISIN | BE0003766806 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | 481M |
|---|---|
| PE Ratio | 39.38 |
| Target Price | 15.75 |
| Dividend Yield | 1.5% |
| Beta | 1.23 |
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IBAB.BR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026